Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:09:27 ON 14 APR 2009

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 09:09:35 ON 14 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 APR 2009  HIGHEST RN 1134263-89-0
DICTIONARY FILE UPDATES:  13 APR 2009  HIGHEST RN 1134263-89-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10572778 broader.str
```



```
chain nodes :
10  13
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
8-13  9-10
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9
exact/norm bonds :
5-7  7-8  8-13  9-10
exact bonds :
6-9  8-9
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


G1:O,S

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
13:CLASS
Generic attributes :
10:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System     : Monocyclic




L1      STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1              STR
```



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	0.70

FILE 'CAPLUS' ENTERED AT 09:09:51 ON 14 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Apr 2009 VOL 150 ISS 16
FILE LAST UPDATED: 13 Apr 2009 (20090413/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1 SSS full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:09:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 85815 TO ITERATE

100.0% PROCESSED 85815 ITERATIONS 332 ANSWERS
SEARCH TIME: 00.00.04

L2 332 SEA SSS FUL L1

L3 37 L2

=> d ibib abs hitstr l-
YOU HAVE REQUESTED DATA FROM 37 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:140234 CAPLUS Full-text
DOCUMENT NUMBER: 150:199381
TITLE: A new combination of (a) an α-4-β-2-neuronal nicotinic agonist and (b) a glycogen synthase kinase 3 (GSK3) inhibitor
INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid; Bencherif, Merouane
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Targacept, Inc.
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017455	A1	20090205	WO 2008-SE50898	20080729

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-952690P P 20070730

AB The present invention related to a combination of (a) a α4β2-neuronal nicotinic agonist and (b) a GSK3 inhibitor. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders such as dementia and/or Alzheimer's Disease.

IT 612487-70-4 612487-72-6,
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile 612487-75-9,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-82-6,
2-Hydroxy-3-[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-

carbonitrile 612487-90-6,
2-Hydroxy-3-[5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-99-7 612488-07-0,
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-6-carbonitrile 612488-33-2 612488-52-5,
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol 593345-96-9 733737-00-3
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(combination of an α-4-β-2-neuronal nicotinic agonist and a glycogen synthase kinase 3 (GSK3) inhibitor for dementia therapy)

RN 612487-70-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612487-75-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-82-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-pyrrolidinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612487-90-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-phenyl-1-piperazinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-99-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-07-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-33-2 CAPLUS
CN Methanone, [6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 612488-52-5 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-nitro- (CA INDEX NAME)



RN 698345-96-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:139734 CAPLUS Full-text
DOCUMENT NUMBER: 150:199277
TITLE: New crystalline forms of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate for use to treat GSK3 related conditions and disorders
INVENTOR(S): Erikson, Anders; Profir, Veronica; Sebhatu, Tesfai; Tjerneld, Erica
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 31pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017452	A1	20090205	WO 2008-SE50895	20080729

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-952634P P 20070730

AB The present invention relates to new crystalline forms of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1 H-indole-5-carbonitrile citrate, a Form D, and a Form E, resp., a process for their prepns., pharmaceutical formulations containing said compds. and to the use of said active compds. in therapy, and particularly to GSK3 related conditions and disorders. Thus, to 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5- carbonitrile citrate (4 g, 7.6 mmol) was added water (40 mL) and the slurry heated to 85° until all was dissolved; then the solution was cooled to 45° over 30 min, followed by further cooling down to 5° over 20 h; the crystals were filtered and washed with ethanol; drying in a vacuum at 50° gave 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5- carbonitrile citrate (3.22 g, 81% yield) with a purity of 98.9%.

IT 945633-71-6, 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile citrate 1110652-72-6
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(crystalline forms of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate for use to treat GSK3 related conditions and disorders)

RN 945633-71-6 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 1110652-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate, hydrate (1:1:1) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:139703 CAPLUS Full-text
DOCUMENT NUMBER: 150:222265
TITLE: New therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958
INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017453	A1	20090205	WO 2008-SE50896	20080729

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-952641P P 20070730

AB The present invention relates to a combination of (a) an antipsychotic and (b) a GSK3 inhibitor. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating psychiatric disorders; particularly, cognitive impairment disorders in psychotic disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of psychiatric disorders; particularly, cognitive impairment disorders in psychotic disorders.

IT 612487-70-4 612487-72-6, 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile 612487-75-9, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-82-8, 2-Hydroxy-3-[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile 612487-90-8, 2-Hydroxy-3-[5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-99-7 612488-07-0, 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-6-carbonitrile 612488-33-2 612488-52-5, 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol 698345-96-9, 2-Hydroxy-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indole-5-carbonitrile 733737-00-3
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958)

RN 612487-70-4 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612487-75-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-82-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-pyrrolidinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612487-90-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-phenyl-1-piperazinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-99-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-07-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-33-2 CAPLUS
CN Methanone, [6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 612488-52-5 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-nitro- (CA INDEX NAME)



RN 698345-96-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:138859 CAPLUS Full-text
DOCUMENT NUMBER: 150:222260
TITLE: New therapeutic combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an α7-nicotinic agonist
INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 59pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017454	A1	20090205	WO 2008-SE50897	20080729

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-952651P P 20070730

AB The present invention related to a combination of (a) a GSK3 inhibitor and (b) an α7- nicotinic agonist. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders such as dementia and/or Alzheimer's Disease.

IT 612487-70-4 612487-72-6 612487-82-8
612487-90-8 612487-99-7 612488-07-0

612488-33-2 612488-52-5 698345-96-9
733737-00-3
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an α7-nicotinic agonist for dementia therapy)

RN 612487-70-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612487-82-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-pyrrolidinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612487-90-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-phenyl-1-piperazinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-99-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-07-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-33-2 CAPLUS
CN Methanone, [6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 612488-52-5 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-nitro- (CA INDEX NAME)



RN 698345-96-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1300811 CAPLUS Full-text
DOCUMENT NUMBER: 149:513869
TITLE: Process for preparation of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile
INVENTOR(S): Delisser, Vern; Hedberg, Martin; Jansson, Annette; Raadevik, Andreas; Ryberg, Per; Thiering, Swantje
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008130312	A1	20081030	WO 2008-SE50432	20080417

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-912527P P 20070418
OTHER SOURCE(S): CASREACT 149:513869; MARPAT 149:513869

AB The present invention pertains to a process for the preparation of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5- carbonitrile as a free base and pharmaceutically acceptable salts thereof, particularly the citrate salt. For example, Et 2-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]acetate was reacted with 3-fluoro-4-nitrobenzonitrile in THF at -20 °C in presence of lithium tert-butoxide to afford an intermediate, which was treated with Degussa heterogeneous catalyst (platinum and vanadium on active carbon) under hydrogen for selective reduction of nitro group to amino group. The reduction product obtained above was treated with citric acid monohydrate at 60-75 °C for 2 h in Bu acetate, DMF, and iso-propanol, cooled to 5 °C over 10 h, and held overnight at 5 °C to gave 75 % yield of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5- carbonitrile citrate as an orange solid. Advantageously, the new process is suitable for large scale industrial manufacturing

IT 1073614-10-4P 1073614-11-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-
5-carbonitrile)

RN 1073614-10-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 1,2-dihydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 1073614-11-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-ethoxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



IT 612487-71-5P 612487-72-6P 945467-87-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-
5-carbonitrile)

RN 612487-71-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 945467-87-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1210838 CAPLUS Full-text
DOCUMENT NUMBER: 149:448395
TITLE: 3-Imidazolylindoles for treatment of proliferative diseases and their preparation
INVENTOR(S): Boettcher, Andreas; Buschmann, Nicole; Furet, Pascal; Groell, Jean-Marc; Kallen, Joerg; Hergovich Lisztwan, Joanna; Masuya, Keiichi; Mayr, Lorenz; Vaupel, Andrea
PATENT ASSIGNEE(S): Novartis A.-G., Switz.
SOURCE: PCT Int. Appl., 260pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008119741	A2	20081009	WO 2008-EP53667	20080327
WO 2008119741	A3	20081204		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-105269 A 20070329
OTHER SOURCE(S): MARPAT 149:448395
GI



I



II

AB The invention relates to 3-heterocyclyl indolyl compds. of formula I, which are capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, resp. Due to their activity, the compds. are useful in the treatment of various disorders and diseases mediated

by the activity of MDM2 and/or MDM4, or variants thereof. Compds. of formula I wherein R1 and R2 are independently (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted aryl and (un)substituted heterocyclyl; R3 is H, halo, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted aryl, carboxy, cyano, etc.; RA is H, (un)substituted alkyl and acyl; X is H, C1-7 (halo)alkyl, C1-7 alkoxy, halo and CN; Y is C1-7 (halo)alkyl, C1-7 alkoxy, halo and CN; and their tautomers, N-oxides and salts thereof, are claimed. Example compound II was prepared by formylation of 6-chloro-1H-indole the resulting 6-chloro-1H-indole-3-carboxaldehyde underwent cyclization with 4-chlorobenzylamine and 1-(isocyanophenylmethanesulfonyl)-4-methylbenzene to give compound II. All the invention compds. were evaluated for their MDM2 and MDM4 inhibitory activity (some data given).

IT 1067655-33-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazolylindoles as MDM2 and MDM4 inhibitors useful in the treatment of proliferative diseases)

RN 1067655-33-7 CAPLUS

CN 1H-Indole-2-sulfonamide, 6-chloro-3-[1-[(4-chlorophenyl)methyl]-4-phenyl-1H-imidazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)



L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:588455 CAPLUS Full-text

DOCUMENT NUMBER: 149:11953

TITLE: Development of a Mild and Robust Method for Large-Scale Palladium-Catalysed Cyanation of Aryl Bromides: Importance of the Order of Addition

AUTHOR(S): Ryberg, Per

CORPORATE SOURCE: Process Chemistry, AstraZeneca PR & D Sodertalje, Soedertaelje, S-151 85, Swed.

SOURCE: Organic Process Research & Development (2008), 12(3), 540-543
CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 149:11953

AB A mild and robust method for the large-scale palladium-catalyzed cyanation of aryl bromides has been developed. The reaction is sensitive to cyanide poisoning of the catalyst, and it was found that the order of adding the reagents had a strong impact on the performance of the reaction. Addition of the cyanide source to a preheated mixture of the other reagents was critical for achieving a robust and scaleable process. This improved protocol allowed

the reaction to be run to full conversion within 3 h at 50 °C on a 6.7 kg scale. Furthermore, it led to the identification of several new efficient catalysts for the reaction.

IT 612487-72-6P
RL: IMF (Industrial manufacture); PREP (Preparation)
(effect of order of addition on large-scale palladium-catalyzed cyanation of aryl bromides)
RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



IT 612488-09-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(effect of order of addition on large-scale palladium-catalyzed cyanation of aryl bromides)
RN 612488-09-2 CAPLUS
CN 1H-Indol-2-ol, 5-bromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1204238 CAPLUS Full-text
DOCUMENT NUMBER: 147:469377
TITLE: Preparation of substituted oxindole derivatives for treating GSK3-related disorders
INVENTOR(S): Arzel, Erwan; Delisser, Vern; Iverson, Suzanne; Ryberg, Per; Raadevik, Andreas
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120102	A1	20071025	WO 2007-SE366	20070418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-793336P P 20060419

OTHER SOURCE(S): CASREACT 147:469377; MARPAT 147:469377

GI



I

AB The present invention relates to new compds. of formula I (wherein R1 is H or OH, Q is N or N+O- with the proviso that when R1 is H then Q is N+O- and when R1 is OH then Q is N) as a free base or a pharmaceutically acceptable salt thereof, in an essentially pure and isolated form, pharmaceutical formulations containing said compds., to the use of said active compds. in therapy, and particularly to GSK3 related disorders, and processes for their prepns. as well as new intermediates. Example compound I (R1=OH, Q=N) was prepared by cyclization of Et 2-(5-cyano-2-nitrophenyl)-2-hydroxy-2-[5-(morpholin-4-ylmethyl)pyridin-2- yl]acetate (preparation given). In a GSK3β scintillation proximity assay the Ki values for the compds. of formula I are in the range of 0.001 nM to 10 μM.

IT 952723-36-3P, 2-Hydroxy-3-[5-[(4-oxidomorpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of substituted oxindole derivs. for treating GSK3-related disorders)

RN 952723-36-3 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-oxido-4-morpholinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



IT 612487-72-6, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile
RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(preparation of substituted oxindole derivs. for treating GSK3-related disorders)
RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:999184 CAPLUS Full-text
DOCUMENT NUMBER: 147:330449
TITLE: New salts of an indole derivative and their pharmaceutical uses
INVENTOR(S): Berg, Anna-Lena; Bhat, Ratan; Sebhatu, Tesfai; Staahle, Erica
PATENT ASSIGNEE(S): Astrazeneca A/B, Swed.
SOURCE: PCT Int. Appl., 37pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007100282	A1	20070907	WO 2007-SE89	20070131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1991539	A1	20081119	EP 2007-709305	20070131
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2008DN06433	A	20081024	IN 2008-DN6433	20080723
CN 101389623	A	20090318	CN 2007-80006973	20080827
PRIORITY APPLN. INFO.:			US 2006-777348P	P 20060228
			WO 2007-SE89	W 20070131

AB The present invention relates to new salts of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5- carbonitrile (I), processes for their preparation, pharmaceutical formulations containing the salts and to the use of the active salts in therapy, and particularly to GSK3 related disorders. I was suspended in EtOH and fumaric acid, and then the solution was heated to 40° to give the fumarate salt.

IT 945467-88-9P 945467-89-0P 945467-90-3P
945467-91-4P 945467-92-5P 945467-93-6P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(salts of indole derivative and their pharmaceutical uses)

RN 945467-88-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 945467-89-0 CAPLUS

CN Ethanesulfonic acid, compd. with 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-1H-indole-5-carbonitrile (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



RN 945467-90-3 CAPLUS
CN 1,2-Ethanedisulfonic acid, compd. with
2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-1H-indole-5-carbonitrile
(1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 110-04-3
CMF C2 H6 O6 S2



RN 945467-91-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-
pyridinyl]-, phosphate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 7664-38-2
CMF H3 O4 P

RN 945467-92-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, (2E)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 945467-93-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 612487-72-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(salts of indole derivative and their pharmaceutical uses)
RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:873822 CAPLUS Full-text
DOCUMENT NUMBER: 147:243348
TITLE: Pharmaceutical use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base or salts
INVENTOR(S): Berg, Anna-Lena; Bhat, Ratan
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007089192	A1	20070809	WO 2007-SE87	20070131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1981500	A1	20081022	EP 2007-709303	20070131
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101378754	A	20090304	CN 2007-80004363	20080801

PRIORITY APPLN. INFO.:

US 2006-764551P	P	20060202
US 2006-777348P	P	20060228
WO 2007-SE87	W	20070131

AB The present invention relates to a new use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation and bone mineral d. The present invention further relates to a method of prevention and/or treatment of these disorders or conditions.

IT 612487-72-6, 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(therapeutic use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base or salts)

RN 612487-72-6 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



IT 612487-72-6DP, salts 945467-87-8P 945467-88-9P 945467-89-0P 945467-90-3P 945467-91-4P 945467-92-5P 945467-93-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(therapeutic use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base or salts)

RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 945467-87-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 945467-88-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 945467-89-0 CAPLUS
CN Ethanesulfonic acid, compd. with 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-1H-indole-5-carbonitrile (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



RN 945467-90-3 CAPLUS
CN 1,2-Ethanedisulfonic acid, compd. with 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-1H-indole-5-carbonitrile

(1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 110-04-3
CMF C2 H6 O6 S2

RN 945467-91-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, phosphate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 7664-38-2
CMF H3 O4 P

RN 945467-92-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, (2E)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 945467-93-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:873770 CAPLUS Full-text
DOCUMENT NUMBER: 147:243347
TITLE: Citrate salt of an indole derivative and its pharmaceutical use
INVENTOR(S): Berg, Anna-Lena; Bhat, Ratan; Sebhatu, Tesfai; Staahle, Erica
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 32pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007089191	A1	20070809	WO 2007-SE86	20070131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007210336	A1	20070809	AU 2007-210336	20070131
CA 2641900	A1	20070809	CA 2007-2641900	20070131
EP 1981869	A1	20081022	EP 2007-709302	20070131
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20070203137	A1	20070830	US 2007-670681	20070202
IN 2008DN06242	A	20080926	IN 2008-DN6242	20080717
MX 2008009719	A	20080904	MX 2008-9719	20080729
CN 101379053	A	20090304	CN 2007-80004153	20080731
KR 2008098022	A	20081106	KR 2008-719047	20080801
NO 2008003784	A	20081013	NO 2008-3784	20080902
US 20090023732	A1	20090122	US 2008-162540	20081001
PRIORITY APPLN. INFO.:			US 2006-764551P P	20060202
			WO 2007-SE86 W	20070131

AB The present invention relates to a new pharmaceutically acceptable salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1 H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing

said salt and to the use of said active salt in therapy, and particularly to GSK3 related conditions and disorders.

IT 945467-87-8P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(citrate salt of an indole derivative and its pharmaceutical use)

RN 945467-87-8 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:?) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 77-92-9
CMF C6 H8 O7



IT 612487-72-6, 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile
RL: RCT (Reactant); RACT (Reactant or reagent)
(citrate salt of an indole derivative and its pharmaceutical use)

RN 612487-72-6 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:873564 CAPLUS Full-text
DOCUMENT NUMBER: 147:257783
TITLE: Process for preparing 2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile and its salts using new intermediates and palladium cyanation catalysts
INVENTOR(S): Erbeck, Silke; Hedberg, Martin; Nussbaumer, Thomas; Ryberg, Per; Zistler, Andrea
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007089193	A1	20070809	WO 2007-SE88	20070131

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-764542P P 20060202
OTHER SOURCE(S): CASREACT 147:257783; MARPAT 147:257783

AB The invention relates to a new process for the manufacture of the compound 2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5- carbonitrile (I) and its pharmaceutically acceptable salts thereof, particularly the 2-hydroxy-3-[5- (morpholin-4-ylmethyl)pyridin-2-yl]1H- indole-5-carbonitrile citrate, which are useful for the treatment of cognitive disorders, Alzheimer disease, dementia, chronic and acute neurodegenerative diseases, bipolar disorders, schizophrenia, diabetes, hair loss etc., via new intermediates and use of palladium catalysts in the cyanation step. Specifically, the method involves condensation of 5-haloxindole with (6-halo-pyridin-3-yl)(morpholin-4-yl)methanone (halo independently = Cl, Br or I) to generate new intermediates [6-(5-halo-2-hydroxy-1H-indol-3-yl)pyridin-3-yl](morpholin-4-yl)methanone (II) for preparing I. Selective reduction of II followed by decomplexation gives 5-halo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol (III). Catalytic cyanation of III using palladium catalysts in a robust condition provides I. Thus, e.g., I was prepared in 90% yield on a large scale (5.2 kg) by cyanation of 5-bromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H- indol-2-ol (preparation given) with zinc cyanide in the presence of di-μ-bromobis(tri-tert-butylphosphine)dipalladium as a catalyst and zinc-dust as an additive. The process is robust for large scale cyanation under mild conditions.

IT 519487-72-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; method for preparing 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile and its salts using new intermediates and palladium cyanation catalysts)

RN 612487-72-6 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



IT 612488-09-2P, 5-Bromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol 945633-70-5P, [6-(5-Bromo-2-hydroxy-1H-indol-3-yl)pyridin-3-yl]morpholin-4-ylmethanone

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; method for preparing 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile and its salts using new intermediates and palladium cyanation catalysts)

RN 612488-09-2 CAPLUS

CN 1H-Indol-2-ol, 5-bromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 945633-70-5 CAPLUS

CN Methanone, [6-(5-bromo-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



IT 945633-71-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile citrate

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for preparing 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile and its salts using new intermediates and

palladium cyanation catalysts)
RN 945633-71-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (CA INDEX NAME)

CM 1

CRN 612487-72-6
CMF C19 H18 N4 O2



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1350295 CAPLUS Full-text
DOCUMENT NUMBER: 144:88168
TITLE: Preparation of indol-2-ol compounds containing heterocycle moiety as kinase inhibitors
INVENTOR(S): Bressi, Jerome C.; Gangloff, Anthony R.; Hosfield, David J.; Jennings, Andrew John; Paraselli, Bheema R.; Stafford, Jeffrey Alan
PATENT ASSIGNEE(S): Takeda San Diego, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123672	A2	20051229	WO 2005-US20890	20050613
WO 2005123672	A3	20060302		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

EP 1773807 A2 20070418 EP 2005-763319 20050613

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

JP 2008502687 T 20080131 JP 2007-516629 20050613

US 20080153869 A1 20080626 US 2007-570315 20070920

PRIORITY APPLN. INFO.: US 2004-579787P P 20040614

WO 2005-US20890 W 20050613

OTHER SOURCE(S): CASREACT 144:88168; MARPAT 144:88168

GI



I



II

AB Title compds. I, II [J, K, L, Y = C, N; M = CH, N; X, Z = C, N, O, etc.; R3, R4, R5 = H, halo, amino, etc.; R3 and R4, or R4 and R5 are taken together to form (un)substituted ring, with the proviso that R3, R4 and/or are absent when J,K and/or L resp. are nitrogen; R7 = H, substituent convertible in vivo to H; R13, R14 = H, alkyl, alkoxy, etc.; R16, R17 = H, alkyl, heterocycloalkyl, etc.; further details on X, Y, Z are given.] and their pharmaceutically acceptable salts were prepared For instance, general procedure is provided for the preparation of 3-(2-amino-6-methylpyrimidin-4-yl)-1H-indol-2-ol (III). In AIK (aurora-A kinase) inhibition assays, exemplified compound III exhibited the IC50 value of <100,000 nM. Compds. I and II are claimed useful for the treatment of inflammation, cancer, etc.

IT 872174-41-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of indol-2-ol compds. containing heterocycle moiety as kinase inhibitors for treatment of inflammation, cancer, etc.)

RN 872174-41-9 CAPLUS

CN 1H-Indol-2-ol, 3-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:588997 CAPLUS Full-text

DOCUMENT NUMBER: 143:115438

TITLE: Preparation of substituted indol-2-ols as kinase inhibitors

INVENTOR(S): Gangloff, Anthony R.; Nowakowski, Jacek; Paraselli, Bheema R.; Stafford, Jeffrey A.; Tennant, Michael G.

PATENT ASSIGNEE(S): Syrrx, Inc., USA

SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061519	A1	20050707	WO 2004-US42631	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050153966	A1	20050714	US 2004-15348	20041217
EP 1694686	A1	20060830	EP 2004-814774	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007514759	T	20070607	JP 2006-545517	20041217
PRIORITY APPLN. INFO.:			US 2003-531202P	P 20031219
			WO 2004-US42631	W 20041217

OTHER SOURCE(S): CASREACT 143:115438; MARPAT 143:115438

GI



I



II

AB The invention relates to compds. I [R3-R6 = H, halo, perhaloalkyl, etc.; or two of R3-R6 are taken together to form a ring, with the proviso that R3-R6 are absent where the ring atom to which R3-R6 are bound is nitrogen; R7 = H or a substituent convertible in vivo to hydrogen; R11-R14 = H, alkyl, alkoxy, etc.; or any two of R11-R14 are taken together to form a ring, with the proviso that R11-R14 are absent when the ring atom to which R11-R14 are bound is nitrogen; A, B, U and V = C, N; J, K, L and M = C, N; W = CR21, N; X = CR15, N; R15 = H, NO2, CN, etc.; R21 = H, NO2, CN, etc.; with the proviso that at least one of R3-R6 is selected from NH2, furanyl, quinolinyl, indolyl, pyridinyl, carboxamidinyl, aminosulfonyl, and arylalkyl (each unsubstituted or substituted), or a substituted sulfonamidyl when A, B, U, V and W are all C; or X = CR15 and R15 is an N-linked moiety when A, B, U, V and W are all C; or X = CR15 and R15 is an S-linked moiety when A, B, U, V and W are all C] that may be used to inhibit kinases, as well as compns. of matter and kits comprising these compds. General procedures for synthesis of compds. I are provided. Over 150 compds. I such as II were prepared and characterized. The exemplified compds. I have been found to have IC50 values in the range of about 0.001 to about 100,000 nM. Other values for IC50 are in the range of about 0.001 to about 10,000 nM for AIK and/or c-KIT. The present invention also relates to methods for inhibiting kinases, as well as treatment methods using compds. I.

IT 857259-54-2P 857259-55-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted indol-2-ols as Aurora-2 and c-KIT inhibitors)

RN 857259-54-2 CAPLUS

CN Butanamide, 4-(dimethylamino)-N-[6-(2-hydroxy-1H-indol-3-yl)-3-pyridinyl]- (CA INDEX NAME)



RN 857259-55-3 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[6-(2-hydroxy-1H-indol-3-yl)-3-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:283287 CAPLUS Full-text
DOCUMENT NUMBER: 142:336240
TITLE: Preparation of heterocyclic-substituted indoles as inhibitors of GSK3β
INVENTOR(S): Berg, Stefan; Hellberg, Sven
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027823	A2	20050331	WO 2004-SE1363	20040921
WO 2005027823	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273771	A1	20050331	AU 2004-273771	20040921
AU 2004273771	B2	20081106		
CA 2538381	A1	20050331	CA 2004-2538381	20040921
EP 1667990	A2	20060614	EP 2004-775465	20040921
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014632	A	20061107	BR 2004-14632	20040921
CN 1886397	A	20061227	CN 2004-80034700	20040921
JP 2007506734	T	20070322	JP 2006-527944	20040921
IN 2006DN01198	A	20070803	IN 2006-DN1198	20060307
US 20080275041	A1	20081106	US 2006-572778	20060321
MX 2006003195	A	20060623	MX 2006-3195	20060322
PRIORITY APPLN. INFO.:			SE 2003-2546 A	20030924
			AU 2003-216026 A3	20030328
			WO 2004-SE1363 W	20040921

OTHER SOURCE(S): CASREACT 142:336240; MARPAT 142:336240
GI



I

AB Title compds. I [P = 5-6-membered heteroarom. ring; R1 = H; R2 = alkyl, CN, halo, etc.; R3 = alkyl, CN, NO2, carboxy, etc.; m, n = 0-4] and derivs. are prepared For instance, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-6-carbonitrile is prepared by the reaction of 2-oxoindoline-6-carbonitrile and 1-[(6-chloro-1-oxidopyridin-3-yl)carbonyl]-4-methylpiperazine (preparation given). Ki of selected compds. of the invention was 20 μM for GSK3β. I are useful for the treatment of, e.g., Alzheimer's Disease.

IT 698345-96-9P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 848474-13-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxylic acid methyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic-substituted indoles as inhibitors of GSK3β)

RN 698345-96-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848474-13-5 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-, methyl ester (CA INDEX NAME)



IT 848472-54-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-

yl)carbonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-55-9P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(morpholin-4-yl)ethyl]nicotinamide hydrochloride 848472-56-0P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide hydrochloride 848472-57-1P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide 848472-58-2P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide hydrochloride 848472-59-3P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide hydrochloride 848472-60-6P, 6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide 848472-62-8P, 2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-64-0P, 3-[5-[[4-[2-(Dipropylamino)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848472-66-2P, 3-[5-[[4-[2-(Dipropylamino)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile 848472-68-4P, 2-Hydroxy-3-[5-[[4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-70-8P, 2-Hydroxy-3-[5-[[4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-72-0P, 2-Hydroxy-3-[5-[[4-[2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-74-2P, 2-Hydroxy-3-[5-[[4-[2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-76-4P, 2-Hydroxy-3-[5-[[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-78-6P, 2-Hydroxy-3-[5-[[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-80-0P, 2-Hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-82-2P, 2-Hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848472-84-4P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-86-6P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848472-88-8P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848472-90-2P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[(thiophen-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848472-92-4P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848472-93-5P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide 848472-95-7P, N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-97-9P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-99-1P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-01-8P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[4-(trifluoromethyl)benzyl]-1H-indole-5-carboxamide hydrochloride 848473-03-0P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(trifluoromethyl)benzyl]-1H-indole-5-carboxamide hydrochloride 848473-05-2P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(trifluoromethyl)benzyl]-1H-indole-5-carboxamide 848473-07-4P

, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(trifluoromethoxy)benzyl]-1H-indole-5-carboxamide hydrochloride 848473-03-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[2-(trifluoromethoxy)benzyl]-1H-indole-5-carboxamide 848473-11-0P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[4-(trifluoromethoxy)benzyl]-1H-indole-5-carboxamide hydrochloride 848473-13-2P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-[(thiophene-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-15-4P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-[(thiophene-2-yl)methyl]-1H-indole-5-carboxamide 848473-17-6P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-19-8P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide 848473-21-2P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide hydrochloride 848473-23-4P, 3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide 848473-25-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[(tetrahydrofuran-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-27-8P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-[(tetrahydrofuran-2-yl)methyl]-1H-indole-5-carboxamide 848473-29-0P, N-Benzyl-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-31-4P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-N-propyl-1H-indole-5-carboxamide hydrochloride 848473-33-6P, 2-Hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-35-8P, 2-Hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-39-2P, 2-Hydroxy-N-(4-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-41-6P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-3-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-43-8P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-4-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-45-0P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-47-2P, N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-49-4P, 2-Hydroxy-N-[2-(methylsulfonyl)ethyl]-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-52-9P, 3-(4-Cyanopyridin-2-yl)-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide 848473-54-1P, 3-(5-Cyanopyridin-2-yl)-2-hydroxy-N-[2-[(4-methylpiperazin-1-yl)sulfonyl]ethyl]-1H-indole-5-carboxamide hydrochloride 848473-56-3P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-58-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-sulfonamide hydrochloride 848473-61-0P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-63-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carboxamide hydrochloride 848473-64-3P, 3-[5-[[4-[2-(Dimethylamino)ethyl]piperazin-1-yl]sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848473-65-4P, 2-Hydroxy-N-(2-methoxyethyl)-3-(5-nitropyridin-2-yl)-1H-indole-5-carboxamide hydrochloride 848473-66-5P, N-(2-Cyanoethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-

indole-5-carboxamide hydrochloride 848473-67-6P,
N-(2-Cyanoethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-68-7P,
2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-69-8P, 2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-70-1P, N-Benzyl-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-71-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-propyl-1H-indole-5-carboxamide hydrochloride 848473-72-3P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-73-4P,
N-[2-(Dimethylamino)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-74-5P, 3-(5-Cyanopyridin-2-yl)-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide hydrochloride 848473-75-6P,
2-Hydroxy-3-[5-[(piperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-76-7P,
2-Hydroxy-N-methyl-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-77-8P,
6-Bromo-2-hydroxy-N-methyl-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-78-9P,
6-Bromo-2-hydroxy-N-isopropyl-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-79-0P, 6-Bromo-2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-80-3P,
6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(tetrahydrofuran-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-81-4P, 6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848473-82-5P,
N-[3-(Dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-83-6P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(morpholin-4-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-84-7P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide hydrochloride 848473-85-8P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide 848473-86-9P,
2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-87-0P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-88-1P, 2-Hydroxy-N-(3-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-89-2P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-5-carboxamide hydrochloride 848473-90-5P, 2-Hydroxy-N-(4-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-91-6P,
2-Hydroxy-N-(4-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-92-7P,
N-(Cyanomethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-93-8P,
N-(Cyanomethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-

indole-5-carboxamide 848473-94-9P,
N-(2-Furylmethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-95-0P,
N-(2-Furylmethyl)-2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-96-1P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848473-97-2P,
2-Hydroxy-3-[5-[(piperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848473-98-3P,
2-Hydroxy-3-[5-[(3-oxopiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848473-99-4P,
2-Hydroxy-3-[6-(2-(morpholin-4-yl)ethoxy)pyrimidin-4-yl]-1H-indole-6-carbonitrile hydrochloride 848474-00-0P,
3-[6-[2-(Diisopropylamino)ethoxy]pyrimidin-4-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848474-01-1P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylic acid hydrochloride 848474-02-2P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-indole-5-carboxamide hydrochloride 848474-03-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(thiophene-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848474-04-4P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-05-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(thiophen-2-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-06-6P,
N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-07-7P, N-(2-Cyanoethyl)-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-08-8P, N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-09-9P,
N-(Cyanomethyl)-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-10-2P,
2-Hydroxy-3-[5-(4-methylpiperazinesulfon-1-yl)pyridin-2-yl]-1H-indole-5-carboxylic acid N-[(carbamoyl)methyl]amide hydrochloride 848474-11-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(methylsulfonyl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-14-6P 848474-15-7P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxylic acid N-[(thiophen-2-yl)methyl]amide 848474-16-8P 848474-17-9P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxylic acid benzylamide 848474-18-0P 848474-19-1P,
3-[5-[(Diethylamino)methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carboxylic acid [2-(methanesulfonyl)ethyl]amide 848567-39-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic-substituted indoles as inhibitors of GSK3β)

RN 848472-54-8 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)carbonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-55-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(4-morpholinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-56-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-57-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 848472-58-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-59-3 CAPLUS
CN 3-Pyridinesulfonamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-60-6 CAPLUS
CN 3-Pyridinesulfonamide, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 848472-62-8 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(1-piperazinylsulfonyl)-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-64-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 3-[5-[[4-[2-(dipropylamino)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-66-2 CAPLUS
CN 1H-Indole-6-carbonitrile, 3-[5-[[4-[2-(dipropylamino)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 848472-68-4 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-70-8 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-72-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 848472-74-2 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-76-4 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-(2-methoxyethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-78-6 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-(2-methoxyethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-80-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-82-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-84-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-86-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 848472-88-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-(2-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-90-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-(2-thienylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-92-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-93-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 848472-95-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(acetylamino)ethyl]-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-97-9 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848472-99-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 848473-01-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[4-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-03-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-05-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 848473-07-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[2-(trifluoromethoxy)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-09-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[2-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 848473-11-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-13-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-thienylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-15-4 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 848473-17-6 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-19-8 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 848473-21-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-methoxyethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-23-4 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 848473-25-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[(tetrahydro-2-furanyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-27-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 848473-29-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-31-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-N-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-33-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-35-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-39-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(4-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-41-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(3-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-43-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(4-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-45-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(2-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-47-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(aminosulfonyl)ethyl]-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-49-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(methylsulfonyl)ethyl]-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-52-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(4-cyano-2-pyridinyl)-2-hydroxy-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 848473-54-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(5-cyano-2-pyridinyl)-2-hydroxy-N-[2-[(4-methyl-1-piperazinyl)sulfonyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-56-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-58-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-61-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-63-2 CAPLUS
CN 1H-Indole-6-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-64-3 CAPLUS
CN 1H-Indole-6-carbonitrile, 3-[5-[[4-[2-(dimethylamino)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-65-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-(5-nitro-2-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-66-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-67-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 848473-68-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-69-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-5-yl)ethyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-70-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-71-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-propyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-72-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-73-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(dimethylamino)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-74-5 CAPLUS
CN 1H-Indole-5-carboxamide, 3-(5-cyano-2-pyridinyl)-2-hydroxy-N-(2-methoxyethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-75-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-76-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-methyl-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-77-8 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-methyl-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-78-9 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-(1-methylethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-79-0 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-80-3 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[(tetrahydro-2-furanyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-81-4 CAPLUS
CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-82-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-[3-(dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-83-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-(4-morpholinylsulfonyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-84-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-3-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-85-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 848473-86-9 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-87-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-88-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(3-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-89-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-90-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(4-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-91-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(4-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-92-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-(cyanomethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-93-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-(cyanomethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 848473-94-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-furanylmethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848473-95-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-(2-furanylmethyl)-2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 848473-96-1 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-97-2 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-98-3 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(3-oxo-1-piperazinyl)methyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-99-4 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[6-[2-(4-morpholinyl)ethoxy]-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848474-00-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 3-[6-[2-[bis(1-methylethyl)amino]ethoxy]-4-pyrimidinyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848474-01-1 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848474-02-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-03-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(2-thienylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848474-04-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-05-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(2-thienyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-06-6 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(acetylamino)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-07-7 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-08-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-[2-(aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-09-9 CAPLUS
CN 1H-Indole-5-carboxamide, N-(cyanomethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-10-2 CAPLUS
CN 1H-Indole-5-carboxamide, N-(2-amino-2-oxoethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 848474-11-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-14-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(2-thienylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 848474-15-7 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(2-thienylmethyl)- (CA INDEX NAME)



RN 848474-16-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 848474-17-9 CAPLUS
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 848474-18-0 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 848474-19-1 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)



RN 848567-90-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-(3-amino-3-oxopropyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



IT 848473-37-0, Methyl 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic-substituted indoles as inhibitors of GSK3β)

RN 848473-37-0 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, methyl ester (CA INDEX NAME)



IT 848472-43-5P 848472-45-7P, Methyl 2-hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carboxylate 848472-47-9P, Methyl 3-[5-[(diethylamino)methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carboxylate 848472-48-0P, Methyl 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylate hydrochloride 848472-50-4P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylic acid 848472-53-7P, Methyl 3-(4-cyanopyridin-2-yl)-2-hydroxy-1H-indole-5-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic-substituted indoles as inhibitors of GSK3β)

RN 848472-43-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-(6-cyano-2-hydroxy-1H-indol-3-yl)-, ethyl ester (CA INDEX NAME)



RN 848472-45-7 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, methyl ester (CA INDEX NAME)



RN 848472-47-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[5-[(diethylamino)methyl]-2-pyridinyl]-2-hydroxy-, methyl ester (CA INDEX NAME)



RN 848472-48-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 848472-50-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-53-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-(4-cyano-2-pyridinyl)-2-hydroxy-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:199862 CAPLUS Full-text
DOCUMENT NUMBER: 142:447077
TITLE: The reaction between 3-aminocrotonates and oxindol-3-ylidene derivatives: synthesis of highly substituted pyrroles
AUTHOR(S): Rehn, Stanley; Bergman, Jan
CORPORATE SOURCE: Unit for Organic Chemistry, Department of Biosciences, Karolinska Institute and Soedertoern University College, Huddinge, SE-141 57, Swed.
SOURCE: Tetrahedron (2005), 61(12), 3115-3123
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:447077

AB The reaction between 3-aminocrotonates and 3-acetonylideneoxindole in refluxing toluene resulted in 2-pyrrol-3'-yloxindoles in high yields (around 90%). At room temperature the 2-pyrrol-3'-yloxindoles exists as keto-enol tautomers. Treatment with POCl3 yielded the 2-chloro-3-pyrrolyl indole, which gave the pyrrolo annulated indolopyran-2-one upon basic hydrolysis of 2-chloro-3-pyrrolyl indole Me ester.

IT 851085-22-8P 851085-24-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tautomerism of pyrrolyloxindoles)

RN 851085-22-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2-hydroxy-1H-indol-3-yl)-2,5-dimethyl-, ethyl ester (CA INDEX NAME)



RN 851085-24-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2-hydroxy-1H-indol-3-yl)-1,2,5-trimethyl-, methyl ester (CA INDEX NAME)



IT 851085-23-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tautomerism of pyrrolyloxindoles)
RN 851085-23-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-(2-hydroxy-1H-indol-3-yl)-2,5-dimethyl-, methyl ester (CA INDEX NAME)



IT 851085-18-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(reactions of pyrrolyloxindoles)
RN 851085-18-2 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2-[(ethoxycarbonyl)oxy]-3-[4-(methoxycarbonyl)-1,2,5-trimethyl-1H-pyrrol-3-yl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:493561 CAPLUS Full-text
DOCUMENT NUMBER: 141:54365

TITLE:	Preparation of 1,3,5-triazines as kinase inhibitors for treatment of angiogenesis or vasculogenesis
INVENTOR(S):	Armistead, David M.; Bemis, Jean E.; Buchanan, John L.; Dipietro, Lucian V.; Elbaum, Daniel; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Kim, Joseph L.; Marshall, Teresa L.; Novak, Perry M.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.; Zhu, Xiaotian
PATENT ASSIGNEE(S):	Amgen Inc., USA
SOURCE:	U.S. Pat. Appl. Publ., 300 pp., Cont. of U.S. Ser. No. 85,053, abandoned. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20040116388	A1	20040617	US 2003-699518		20031031
US 7074789	B2	20060711			
ES 2306671	T3	20081116	ES 2000-972036		20001006
PRIORITY APPLN. INFO.:			US 1999-158176P	P	19991007
			US 1999-166978P	P	19991123
			US 1999-170378P	P	19991213
			US 2000-183263P	P	20000217
			US 2000-215576P	P	20000630
			US 2000-219801P	P	20000720
			US 2000-685053	B1	20001006
OTHER SOURCE(S):	MARPAT 141:54365				

GI



I II

AB Title compds. I [wherein R1 and R2 = independently R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, (un)substituted heterocyclyl, alkyl; R3 = independently aryl, (un)substituted Ph, heteroaryl; R5 = independently H, alkynyl, cycloalkenyl, aryl, R9, (un)substituted (cyclo)alkyl, alkenyl; R6 = independently COR5, CO2R5, CONR5R5, C(=NR5)NR5R5, SO1-2R5; R8 = independently (un)substituted (hetero)monocyclyl, (hetero)bicyclyl, (hetero)tricyclyl] were prepared as inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer. Examples include a number of general synthetic methods, specific exptl. details for the preparation of selected invention compds., and phys. and bioassay data. For instance, 2,4-dichloro-1,3,5-triazine was coupled with 3,4,5-trimethoxyaniline in the presence of diisopropylethylamine in DMF to give the triazinamine (37%). Subsequent reaction with 4-aminoveratrole using diisopropylethylamine in EtOH provided II (66%). The latter was one of over 950 invention compds. tested for activity against the EGFR-1, IGFR-1, Akt3-1, Met-1, KDR-1, Zap-1, Lck-1, Itk-1, PDGFRB-1, Tek-1, ErbB2-2, EPHB4-1, ErbB4-1, FGFR1-1, Flt-1, Fyn-1, Hck-1, Lyn-1, Ret-1, and/or Src-1 receptors with IC50 values in ranges from

<0.4 μg/mL to >4.5 μg/mL. Thus, I and their compns. are useful for the treatment of diseases or conditions involving angiogenesis or vasculogenesis (no data).

IT 333728-93-1P 333729-76-3P 333730-27-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(kinase inhibitor; preparation of triazines as kinase inhibitors for treatment of angiogenesis or vasculogenesis)

RN 333728-93-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



RN 333729-76-3 CAPLUS
CN 1H-Indol-2-ol, 1-methyl-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



RN 333730-27-1 CAPLUS
CN 1H-Indol-2-ol, 5-chloro-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:41121 CAPLUS Full-text
DOCUMENT NUMBER: 140:94045
TITLE: Preparation of hypoglycemic imidazoline compounds
INVENTOR(S): Takeuchi, Kumiko; Jirousek, Michael Robert; Paal, Michael; Ruhter, Gerd; Schotten, Theo
PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 106 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040009976	A1	20040115	US 2002-135963	20020430
PRIORITY APPLN. INFO.:			US 2002-135963	20020430

OTHER SOURCE(S): MARPAT 140:94045
GI

I

AB The title compds. I [X = O, S, NR5 with R5 = H, alkyl, protecting group; R1, R1', R2, R3 = H, alkyl; R1 and R2 form a bond and R1' and R3 are H, alkyl; or R1 and R2 form a carbocyclic ring; R4 = (un)substituted indolyl, naphthyl, quinolinyl, etc.; n = 0-2], useful for treating diabetes, diabetic complications, metabolic disorders or related diseases where impaired glucose disposal is present, were prepared and formulated. E.g., preparation of 5-chloro-2-methyl-3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indole is described.

IT 227800-70-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hypoglycemic imidazolines)

RN 227800-70-6 CAPLUS

CN 1H-Indole, 5-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-2-(phenylthio)- (CA INDEX NAME)



L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:796689 CAPLUS Full-text
DOCUMENT NUMBER: 139:323431
TITLE: Preparation of heterocyclyl-substituted 2-oxindoles and 2,3-dihydro-1H-indol-2-ols as glycogen synthase kinase-3 inhibitors
INVENTOR(S): Berg, Stefan; Hellberg, Sven; Nyloef, Martin; Xue, Yafeng

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082853	A1	20031009	WO 2003-SE508	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476343	A1	20031009	CA 2003-2476343	20030328
AU 2003216026	A1	20031013	AU 2003-216026	20030328
AU 2003216026	B2	20081211		
EP 1492785	A1	20050105	EP 2003-745498	20030328
EP 1492785	B1	20081203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008196	A	20050111	BR 2003-8196	20030328
CN 1642938	A	20050720	CN 2003-807389	20030328
JP 2005526814	T	20050908	JP 2003-580319	20030328
JP 3989444	B2	20071010		
CN 1923812	A	20070307	CN 2006-10153714	20030328
NZ 534664	A	20070629	NZ 2003-534664	20030328
EP 1961748	A2	20080827	EP 2008-157461	20030328
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK				
RU 2338742	C2	20081120	RU 2004-125146	20030328
AT 416171	T	20081215	AT 2003-745498	20030328
MX 2004009163	A	20041207	MX 2004-9163	20040921
ZA 2004007665	A	20050829	ZA 2004-7665	20040922
US 20050153987	A1	20050714	US 2004-509268	20040927
US 7399780	B2	20080715		
NO 2004004432	A	20041019	NO 2004-4432	20041019
JP 2007224051	A	20070906	JP 2007-155810	20070613

PRIORITY APPLN. INFO.:			
	SE 2002-979	A	20020328
	CN 2003-807389	A3	20030328
	EP 2003-745498	A3	20030328
	JP 2003-580319	A3	20030328
	WO 2003-SE508	W	20030328

OTHER SOURCE(S): MARPAT 139:323431
GI



AB Title compds. I and II [wherein P = 5- or 6-membered heteroarom. ring; R1 = H; R2 and R3 = independently halo, NO2, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, CHO, COR4, CO2R4, CH2F, CHF2, CF3, OCH2F, OCHF2, OCF3, OCO2R4, NR4OR5, NR4CO2R5, SO3R4, XR6; R4 = H, alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, alkyl-NR14R15, or (un)substituted heterocyclyl; R5 = H or (un)substituted alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, or alkyl-NR14R15; or NR4R5 = (un)substituted heterocyclyl; R6 = (un)substituted Ph or heterocyclyl; R7, R9, and R12 = independently H or alkyl; R8 ,R10, R11, and R13 = independently alkyl; R14 and R15 = independently H or alkyl(cycloalkyl); or NR14R15 = (un)substituted heterocyclyl; X = direct bond, O, COR7R8, SO2NR9R10, or NR12R13; OCOR4 (un)substituted alkyl or alkoxy; m = 0-4; n = 0-4; and their pharmaceutically acceptable salts thereof] were prepared as glycogen synthase kinase-3 (GSK3) inhibitors. For example, reduction of 5-cyanooxindole with NaH in DMF, followed by coupling with 2-chloro-N-[2-(dimethylamino)ethyl]isonicotinamide in DMF provided the title indolol III (5%). In ATP competition assays, compds. of the invention inhibited recombinant human GSK3β with Ki values in the range of about 0.001 nM to about 10,000 nM (no specific values given). Thus, I, II, and their pharmaceutical formulations are useful for the treatment of a variety of neurodegenerative and dementia related diseases, including Alzheimer's disease (no data).

IT 612487-72-6P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-75-9P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-77-1P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide 612487-80-6P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide 612487-82-8P, 2-Hydroxy-3-[5-[(pyrrolidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-85-1P, 2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-87-3P, 2-Hydroxy-3-[5-[[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-07-0P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile 612488-09-2P, 5-Bromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol 612488-11-6P, 5,6-Dibromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol 612488-22-9P,

3-[3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol 612488-31-0P,
6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide 612488-33-2P,
3-[5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol 612488-35-4P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide 612488-38-7P,
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide 612488-41-2P,
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide 612488-52-5P,
3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(GSK3 inhibitor; preparation of (heterocyclyl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612487-72-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612487-75-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-77-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)



RN 612487-80-6 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 612487-82-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-pyrrolidinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612487-85-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612487-87-3 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612488-07-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-09-2 CAPLUS
CN 1H-Indol-2-ol, 5-bromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-11-6 CAPLUS
CN 1H-Indol-2-ol, 5,6-dibromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-22-9 CAPLUS
CN 1H-Indol-2-ol, 3-[3-bromo-5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-nitro- (CA INDEX NAME)



RN 612488-31-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 612488-33-2 CAPLUS
CN Methanone, [6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 612488-35-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 612488-38-7 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 612488-41-2 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethyl- (CA INDEX NAME)



RN 612488-52-5 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-nitro- (CA INDEX NAME)



IT 612487-68-9P, 2-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]isonicotinamide 612487-69-1P, 2-Hydroxy-3-[4-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-70-4P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-71-5P, 2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-73-7P, 2-Hydroxy-3-[6-[2-(morpholin-4-yl)ethoxy]pyrimidin-4-yl]-1H-indole-5-carbonitrile 612487-74-8P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-76-0P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide hydrochloride 612487-78-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-79-3P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide hydrochloride 612487-81-7P, 2-Hydroxy-3-[5-[(pyrrolidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-83-9P, 2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-86-2P, 2-Hydroxy-3-[5-[[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612487-88-4P, 3-[5-[[3-(Dimethylamino)pyrrolidin-1-yl]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-89-5P, 2-Hydroxy-3-[5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-90-8P, 2-Hydroxy-3-[5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-91-9P, 3-[5-[(Azetidin-1-yl)methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-92-0P, 2-Hydroxy-3-[5-[[4-[2-nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-93-1P, 3-[5-[[(2-Cyanoethyl)(ethyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-94-2P,

3-[5-[[(4-Chlorobenzyl)(methyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-95-3P,
3-[5-[[[(2-Furyl)methyl](methyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-96-4P,
2-Hydroxy-3-[5-[[methyl(phenyl)amino]methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612487-97-5P,
2-Hydroxy-3-[5-[(3-methylpiperidin-1-yl)methyl]pyridin-2-yl]I-1H-indole-5-carbonitrile 612487-98-6P,
3-[5-[[Cyclohexyl(methyl)amino]methyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile 612487-99-7P,
2-Hydroxy-3-[5-[(piperidin-1-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-00-3P,
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-01-4P,
6-Chloro-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-03-6P,
3-[5-[(Morpholin-4-yl)carbonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol 612488-05-8P, 6-Bromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-06-9P,
2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 612488-08-1P,
5-Bromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-10-5P,
5,6-Dibromo-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-14-9P,
3-[5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride 612488-15-0P,
2-Hydroxy-3-[5-[[4-(3-methylbutyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612488-16-1P,
2-Hydroxy-3-[5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612488-17-2P,
3-[5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride 612488-18-3P,
3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-(pyridin-3-yl)-1H-indol-2-ol 612488-19-4P, 3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-(thien-2-yl)-1H-indol-2-ol hydrochloride 612488-20-7P,
5-(2-Furyl)-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-21-8P,
3-[3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride 612488-23-0P,
3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-(trifluoromethyl)-1H-indol-2-ol hydrochloride 612488-24-1P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 612488-25-2P,
N-[(1-Ethylpyrrolidin-2-yl)methyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinamide hydrochloride 612488-26-3P,
6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(morpholin-4-yl)ethyl]nicotinamide hydrochloride 612488-27-4P,
6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-methyl-N-(1-methylpiperidin-4-yl)nicotinamide hydrochloride 612488-28-5P,
5-Nitro-3-[5-[[4-(pyrrolidin-1-yl)piperidin-1-yl]carbonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-29-6P,
3-[5-[[3-(Dimethylamino)pyrrolidin-1-yl]carbonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride 612488-30-9P,
N-[2-(Dimethylamino)-1-methylethyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinamide hydrochloride 612488-32-1P,
6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(pyrrolidin-1-yl)ethyl]nicotinamide fumarate 612488-34-3P,
3-[5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol fumarate 612488-36-5P, 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-

(pyrrolidin-1-yl)ethyl]nicotinamide fumarate 612488-37-6P,
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-sulfonamide hydrochloride 612488-40-1P,
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide fumarate 612488-42-3P,
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide fumarate 612488-43-4P,
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide 612488-44-5P,
2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-45-6P,
2-Hydroxy-3-[5-[(morpholin-4-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-46-7P,
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(2-methylthiazol-4-yl)-1H-indol-2-ol hydrochloride 612488-48-9P,
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(thiazol-4-yl)-1H-indol-2-ol fumarate 612488-49-0P,
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(oxazol-5-yl)-1H-indol-2-ol 612488-50-3P,
3-[5-[(Morpholin-4-yl)methyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride 612488-55-8P,
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide fumarate 612488-57-0P,
2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile fumarate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GSK3 inhibitor; preparation of (heterocyclyl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612487-68-0 CAPLUS
CN 4-Pyridinecarboxamide, 2-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 612487-69-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[4-[(4-methyl-1-piperazinyl)carbonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612487-70-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-71-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



RN 612487-73-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[6-[2-(4-morpholinyl)ethoxy]-4-pyrimidinyl]- (CA INDEX NAME)



RN 612487-74-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



RN 612487-76-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methyl-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612487-78-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612487-79-3 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612487-81-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-pyrrolidinylmethyl)-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612487-83-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612487-86-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612487-88-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612487-89-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperidinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-90-8 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-phenyl-1-piperazinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-91-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-(1-azetidinylmethyl)-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612487-92-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-93-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[[(2-cyanoethyl)ethylamino]methyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612487-94-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[[[(4-chlorophenyl)methyl]methylamino]methyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612487-95-3 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[[(2-furanylmethyl)methylamino]methyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612487-96-4 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(methylphenylamino)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-97-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(3-methyl-1-piperidinyl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 612487-98-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(cyclohexylmethylamino)methyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612487-99-7 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(1-piperidinylmethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-00-3 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



RN 612488-01-4 CAPLUS
CN 1H-Indol-2-ol, 6-chloro-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-03-6 CAPLUS
CN Methanone, [6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]-4-morpholinyl-
(CA INDEX NAME)



RN 612488-05-8 CAPLUS
CN 1H-Indol-2-ol, 6-bromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-,
hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-06-9 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-
pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-08-1 CAPLUS
CN 1H-Indol-2-ol, 5-bromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-10-5 CAPLUS
CN 1H-Indol-2-ol, 5,6-dibromo-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-14-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(phenylmethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-15-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(3-methylbutyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-16-1 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(1-methylethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-17-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-18-3 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-(3-pyridinyl)- (CA INDEX NAME)



RN 612488-19-4 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-(2-thienyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-20-7 CAPLUS
CN 1H-Indol-2-ol, 5-(2-furanyl)-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-21-8 CAPLUS
CN 1H-Indol-2-ol, 3-[3-bromo-5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-23-0 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-(trifluoromethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-24-1 CAPLUS
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-25-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-26-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(4-morpholinyl)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-methyl-N-(1-methyl-4-piperidinyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612488-28-5 CAPLUS
CN Methanone, [6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl][4-(1-pyrrolidinyl)-1-piperidinyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612488-29-6 CAPLUS
CN Methanone, [3-(dimethylamino)-1-pyrrolidinyl][6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612488-30-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)-1-methylethyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)-, hydrochloride (1:?) (CA INDEX NAME)



RN 612488-32-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-31-0
CMF C20 H21 N5 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 612488-34-3 CAPLUS
CN Piperazine, 1-[[6-(2-hydroxy-5-nitro-1H-indol-3-yl)-3-pyridinyl]carbonyl]-4-methyl-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-33-2
CMF C19 H19 N5 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 612488-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-35-4
CMF C21 H21 N5 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-37-6 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



RN 612488-40-1 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-39-8
CMF C18 H19 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 612488-42-3 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethyl-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-41-2
CMF C20 H23 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-43-4 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 612488-44-5 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612488-45-6 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylsulfonyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-46-7 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-(2-methyl-4-thiazolyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612488-48-9 CAPLUS
CN Piperazine, 1-[[6-[2-hydroxy-5-(4-thiazolyl)-1H-indol-3-yl]-3-pyridinyl]sulfonyl]-4-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-47-8
CMF C21 H21 N5 O3 S2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-49-0 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-(5-oxazolyl)- (CA INDEX NAME)



RN 612488-50-3 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-2-pyridinyl]-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



RN 612488-55-8 CAPLUS
CN 3-Pyridinesulfonamide, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-43-4
CMF C21 H23 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-57-0 CAPLUS
CN 1H-1,4-Diazepine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]hexahydro-4-methyl-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-44-5
CMF C20 H21 N5 O3 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 612487-59-9P 612487-60-2P 612487-65-7P, 3-[5-[(Morpholin-4-yl)methyl]-1-oxidopyridin-2-yl]-5-(pyridin-3-yl)-1H-indol-2-ol 612487-66-8P, 3-[5-[(Morpholin-4-yl)methyl]-1-oxidopyridin-2-yl]-5-(thien-2-yl)-1H-indol-2-ol 612487-67-9P, 5-(2-Furyl)-3-[5-[(morpholin-4-yl)methyl]-1-oxidopyridin-2-yl]-1H-indol-2-ol 612487-84-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (heterocyclyl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)
RN 612487-59-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-(2-hydroxy-5-nitro-1H-indol-3-yl)-, ethyl ester (CA INDEX NAME)



RN 612487-60-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-(5-cyano-2-hydroxy-1H-indol-3-yl)-, ethyl ester (CA INDEX NAME)



RN 612487-65-7 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-1-oxido-2-pyridinyl]-5-(3-pyridinyl)- (CA INDEX NAME)



RN 612487-66-8 CAPLUS
CN 1H-Indol-2-ol, 3-[5-(4-morpholinylmethyl)-1-oxido-2-pyridinyl]-5-(2-thienyl)- (CA INDEX NAME)



RN 612487-67-9 CAPLUS
CN 1H-Indol-2-ol, 5-(2-furanyl)-3-[5-(4-morpholinylmethyl)-1-oxido-2-pyridinyl]- (CA INDEX NAME)



RN 612487-84-0 CAPLUS
CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1-oxido-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:711467 CAPLUS Full-text
DOCUMENT NUMBER: 139:307657

TITLE: Catalytic enantioselective synthesis of oxindoles and benzofuranones that bear a quaternary stereocenter

AUTHOR(S): Hills, Ivory D.; Fu, Gregory C.
CORPORATE SOURCE: Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, 20139, USA

SOURCE: Angewandte Chemie, International Edition (2003), 42(33), 3921-3924
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:307657

GI



I



II



III

AB A new method for the catalytic enantioselective rearrangement of O-acylated benzofuranones, e.g. I, and oxindoles to produce their C-acylated isomers, e.g. II, has been reported. This is an efficient carbon-carbon bond-forming reaction that generates a quaternary stereocenter utilizing an iron complex (III) of 4-pyrrolidinopyridine as a planar-chiral catalyst. On the mechanistic side, the authors have crystallog. characterized the presumed intermediate in this process.

IT 610304-98-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(catalytic enantioselective synthesis of oxindoles and benzofuranones that bear a quaternary stereocenter)

RN 610304-98-8 CAPLUS

CN Carbonic acid, 1-methyl-3-(2-thienyl)-1H-indol-2-yl 2,2,2-trichloro-1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:814114 CAPLUS Full-text
DOCUMENT NUMBER: 137:325434
TITLE: Preparation of triazinyl amides as angiogenesis inhibitors
INVENTOR(S): Geuns-Meyer, Stephanie D.; Dipietro, Lucian V.; Kim, Joseph L.; Patel, Vinod F.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083654	A1	20021024	WO 2002-US11675	20020411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030087908	A1	20030508	US 2002-120939	20020410
US 6864255	B2	20050308		

CA 2443366	A1	20021024	CA 2002-2443366	20020411
AU 2002338645	A1	20021028	AU 2002-338645	20020411
EP 1385833	A1	20040204	EP 2002-762087	20020411

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:	US 2001-282977P	P	20010411
	US 2002-120939	A	20020410
	WO 2002-US11675	W	20020411

OTHER SOURCE(S): MARPAT 137:325434

GI

I



II

AB The triazinyl amides I [wherein R1 = (un)substituted Ph or heteroaryl; R2 = H, halo, R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, heterocyclyl, or (un)substituted alkyl, etc.; R3 = Ph or (un)substituted heteroaryl; R5 = H, alkynyl, aryl, R9, or (un)substituted (cyclo)alkyl or (cyclo)alkenyl, etc.; R6 = COR5, CO2R5, CONR5R5, C(=NR5)NR5R5, or SOnR5; R8 and R9 = independently mono-, bi-, or tri-cyclic ring, etc.; n = 1 or 2; aryl = (un)substituted mono-, bi-, or tri-cyclic aromatic ring, etc.; or analogs, prodrugs, and pharmaceutically acceptable salts thereof] were prepared for prophylaxis and treatment of cancer and angiogenesis-related diseases. For example, the triazinyl benzamide II was prepared in a multiple-step synthesis including the final coupling reaction of [4-(2-chlorobenzimidazol-1-yl)-[1,3,5]triazin-2-yl]- (3,4,5-trimethoxyphenyl)amine with 3-amino-N-(4-phenoxyphenyl)benzamide in isopropanol in the presence of DIEA. I showed inhibition of KDR kinase at doses less than 50 μM.

IT 333728-93-1P 333729-76-3P 333730-27-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of triazinyl amides as angiogenesis inhibitors)

RN 333728-93-1 CAPLUS

CN 1H-Indol-2-ol, 3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



RN 333729-76-3 CAPLUS

CN 1H-Indol-2-ol, 1-methyl-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-

2-yl]- (CA INDEX NAME)



RN 333730-27-1 CAPLUS
CN 1H-Indol-2-ol, 5-chloro-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:742304 CAPLUS Full-text
DOCUMENT NUMBER: 138:204903
TITLE: Study on direct benzoannelations of pyrrole and indole systems by domino reactions with 4,5-dicyanopyridazine
AUTHOR(S): Giomi, Donatella; Cecchi, Marco
CORPORATE SOURCE: Dipartimento di Chimica Organica 'Ugo Schiff', Universita di Firenze, Sesto Fiorentino, I-50019, Italy
SOURCE: Tetrahedron (2002), 58(40), 8067-8071
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:204903
AB 4,5-Dicyanopyridazine (I) underwent hetero Diels-Alder [4+2] cycloaddns. on the C(2)-C(3) double bond of pyrrole and indole systems; spontaneous loss of nitrogen from the primary adducts, followed by oxidation processes, afforded the corresponding fully aromatic benzoannelated skeletons in modest and reasonable yields, resp. Competitive attacks of the same systems at the strongly electrophilic C-4 carbon of I, leading to substitution products, were evidenced.
IT 500008-31-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(benzannelations of pyrrole and indole systems by domino reactions with 4,5-dicyanopyridazine)
RN 500008-31-1 CAPLUS
CN 4-Pyridazinecarbonitrile, 5-[2-(ethylthio)-1H-indol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:501900 CAPLUS Full-text
DOCUMENT NUMBER: 135:303820
TITLE: Efficient synthesis of 3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indoles
AUTHOR(S): Hary, U.; Roettig, U.; Paal, M.
CORPORATE SOURCE: Lilly Forschung GmbH, Hamburg, 22419, Germany
SOURCE: Tetrahedron Letters (2001), 42(31), 5187-5189
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:303820
GI



I

AB A simple method for the synthesis of various 3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indoles, e.g. I, is described. Treatment of different substituted indoles with 1-acetylimidazolidin-2-one in the presence of phosphorus oxychloride afforded after hydrolysis in ethanol the corresponding 3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indoles in moderate to good yields.

IT 227800-70-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of imidazolylindoles by coupling of indoles with acetylimidazolidinone)

RN 227800-70-6 CAPLUS

CN 1H-Indole, 5-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-2-(phenylthio)- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:265404 CAPLUS Full-text
DOCUMENT NUMBER: 134:295842
TITLE: Preparation of triazine kinase inhibitors
INVENTOR(S): Armistead, David M.; Bemis, Jean E.; Buchanan, John L.; Dipietro, Lucian V.; Elbaum, Daniel; Habgood, Gregory J.; Kim, Joseph L.; Marshall, Teresa L.; Geuns-Meyer, Stephanie D.; Novak, Perry M.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.; Zhu, Xiaotian
PATENT ASSIGNEE(S): Kinetix Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 376 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025220	A1	20010412	WO 2000-US27811	20001006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2386218	A1	20010412	CA 2000-2386218	20001006
EP 1218360	A1	20020703	EP 2000-972036	20001006
EP 1218360	B1	20080528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511378	T	20030325	JP 2001-528166	20001006
AU 770600	B2	20040226	AU 2001-10754	20001006
AT 396978	T	20080615	AT 2000-972036	20001006
ES 2306671	T3	20081116	ES 2000-972036	20001006
MX 2002003436	A	20020820	MX 2002-3436	20020404

PRIORITY APPLN. INFO.:			
US 1999-158176P	P	19991007	
US 1999-166978P	P	19991123	
US 1999-170378P	P	19991213	
US 2000-183263P	P	20000217	
US 2000-215576P	P	20000630	
US 2000-219801P	P	20000720	
WO 2000-US27811	W	20001006	

OTHER SOURCE(S): MARPAT 134:295842
GI



AB Title triazine compds. (I) [wherein R1 and R2 = independently R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, or (un)substituted heterocyclyl or alkyl; R3 = independently aryl or (un)substituted Ph or heteroaryl; R5 = independently H, (un)substituted (cyclo)alkyl or alkenyl, alkynyl, cycloalkenyl, aryl, or haloalkyl; R6 = independently COR5, CO2R5, CONR5R5, C(NR5)NR5R5, or SOnR5; R8 = independently (un)substituted mono-, di-, or tricyclic ring system comprising 1-3, 1-6, or 1-9 heteroatoms, resp.; n = 1-2] were prepared as inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer. For example, amination of 2,4-dichloro-1,3,5-triazine (preparation given) with 3,4,5-trimethoxyaniline in DMF, followed by a second amination with 4-aminoveratrole in the presence of diisopropylethylamine in EtOH, yielded II. In kinase inhibition studies, II gave IC50 values of < 0.4 μg/mL for KDR-1, PDGFRB-1, and Flt-1; 0.4 to 2.4 μg/mL for Lck-1; 3.5 to 4.5 μg/mL for EGFR-1, Tek-1, and EPGB4-1; and > 4.5 μg/mL for IGFR-1, AKT3-1, Met-1, Zap-1, Itk-1, FGFR1-1, and Fyn-1. I and compns. comprising them are useful for the treatment of disease or disease symptoms related to kinase inhibition, such as angiogenesis or vasculogenesis (no data).

IT 333728-93-1P 333729-76-3P 333730-27-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazine kinase inhibitors for inhibiting angiogenesis or vasculogenesis)

RN 333728-93-1 CAPLUS
CN 1H-Indol-2-ol, 3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



RN 333729-76-3 CAPLUS
CN 1H-Indol-2-ol, 1-methyl-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



RN 333730-27-1 CAPLUS
CN 1H-Indol-2-ol, 5-chloro-3-[4-[(3,4,5-trimethoxyphenyl)amino]-1,3,5-triazin-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:401581 CAPLUS Full-text
DOCUMENT NUMBER: 131:58827
TITLE: Preparation of hypoglycemic imidazoline compounds
INVENTOR(S): Jirousek, Michael Robert; Paal, Michael; Ruhter, Gerd; Schotten, Theo; Stenzel, Wolfgang; Takeuchi, Kumiko
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 136 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 924209	A1	19990623	EP 1998-310461	19981218
EP 924209	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2315226	A1	19990701	CA 1998-2315226	19981218
WO 9932112	A1	19990701	WO 1998-US26974	19981218
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 9932482	A1	19990701	WO 1998-US27080	19981218
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9920030	A	19990712	AU 1999-20030	19981218
AU 9922016	A	19990712	AU 1999-22016	19981218
ZA 9811672	A	20000619	ZA 1998-11672	19981218
JP 2001526286	T	20011218	JP 2000-525419	19981218
EP 1266897	A2	20021218	EP 2002-20546	19981218

EP 1266897		A3	20031203			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, CY, AL						
AT 239013		T	20030515	AT 1998-310461		19981218
PT 924209		T	20030829	PT 1998-310461		19981218
ES 2198033		T3	20040116	ES 1998-310461		19981218
US 6410562		B1	20020625	US 2000-581498		20001208
PRIORITY APPLN. INFO.:				US 1997-68195P	P	19971219
				EP 1998-310461	A3	19981218
				WO 1998-US26974	W	19981218
				WO 1998-US27080	W	19981218

OTHER SOURCE(S): MARPAT 131:58827

GI

I

AB The title compds. I [X = O, S, NR5 with R5 = H, alkyl, protecting group; R1, R1', R2, R3 = H, alkyl; R1 an R2 form a bond an R1' and R3 are H, alkyl; R1 and R2 form a carbocyclic ring; R4 = heterocyclyl; n = 0-2], hypoglycemic agents, were prepared E.g., 5-chloro-2-methyl-3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indole was prepared

IT 227800-70-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hypoglycemic imidazoline compds.)

RN 227800-70-6 CAPLUS

CN 1H-Indole, 5-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-2-(phenylthio)- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1997:707534 CAPLUS Full-text
DOCUMENT NUMBER:	127:346363
ORIGINAL REFERENCE NO.:	127:67962h,67963a
TITLE:	Facile synthesis of benzotriazines and indoles by ring scissions of α-benzotriazol-1-yl hydrazones
AUTHOR(S):	Katritzky, Alan R.; Wang, Jin; Karodia, Nazira; Li, Jianqing

CORPORATE SOURCE: Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL, 32611-7200, USA
SOURCE: Synthetic Communications (1997), 27(22), 3963-3976
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:346363
GI


I


II

AB α-Benzotriazol-1-yl hydrazones were prepared by refluxing the corresponding α-benzotriazol-1-yl ketones with p-tosyl hydrazide or benzenesulfonyl hydrazide. Treatment of the hydrazones with n-butyllithium in the presence of TMEDA gave benzotriazines (I; R = H, Me) or indoles (II; R1 = p-tolyl, 2-furyl).
IT 198216-44-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(benzotriazines and indoles by ring scissions of α-benzotriazol-1-yl hydrazones)
RN 198216-44-3 CAPLUS
CN 1H-Indole, 3-(2-furanyl)-2-phenoxy- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:213284 CAPLUS Full-text
DOCUMENT NUMBER: 122:81059
ORIGINAL REFERENCE NO.: 122:15399a,15402a
TITLE: 2-Ethoxycarbonyloxy-3-ethynylindoles from indol-2(3H)-ones
AUTHOR(S): Beccalli, Egle M.; Marchesini, Alessandro; Pilati, Tullio
CORPORATE SOURCE: Ist. Chim. Org., Univ. Studi Milano, Milano, 20133, Italy
SOURCE: Tetrahedron (1994), 50(44), 12697-712
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 122:81059
GI



I



II

AB The treatment of the 3-[(1-chloro-2-substituted)ethylidene]indol-2(3H)- ones [I; Z = CClCH2R; R = Ph, Me, H, CO2Et, methylthio, 2-thienyl, CH2-CO2Et, methoxy, NH-CO2Me], prepared from indol-2(3H)-one[I; Z = H2], with Et chloroformate and triethylamine gives the Et 3-(ethynyl)-2-(ethoxycarbonyloxy)indole-1-carboxylates II. Some dimeric derivs. of the intermediate allenes have been isolated.

IT 160291-91-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(Ethoxycarbonyloxyethynylindoles from indolones)

RN 160291-91-8 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[(ethoxycarbonyl)oxy]-3-(2-methyl-5-oxazolyl)-, ethyl ester (CA INDEX NAME)



L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:182350 CAPLUS Full-text

DOCUMENT NUMBER: 120:182350

ORIGINAL REFERENCE NO.: 120:31885a,31888a

TITLE: Interactive multivariate analysis of bisindolylmaleimides as potent protein kinase C antagonists

AUTHOR(S): Mager, Peter P.

CORPORATE SOURCE: Inst. Pharmacol. Toxicol., Univ. Leipzig, Leipzig, 7010, Germany

SOURCE: Drug Design and Discovery (1993), 10(3), 231-48
CODEN: DDDIEV; ISSN: 1055-9612

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The isoenzyme protein kinase C (PKC) inhibitory activity of substituted bisindolylmaleimides depends on the mol. weight, the total charge, and dipole moments. The validity of the resulting QSAR equation was investigated by

interactive diagnostic statistics and multivariate simultaneous statistical inference. Mol. mechanics and dynamics can be used to study possible reasons of flagged observations (high-leverage points, influential data, outliers) of QSAR systems.

IT 125313-56-6 125334-43-2
RL: BIOL (Biological study)
(protein kinase C inhibitory activity of, QSAR study of)

RN 125313-56-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[1-methyl-2-(methylthio)-1H-indol-3-yl]- (CA INDEX NAME)



RN 125334-43-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[1-methyl-2-(methylsulfinyl)-1H-indol-3-yl]- (CA INDEX NAME)



L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1992:41230 CAPLUS Full-text
DOCUMENT NUMBER:	116:41230
ORIGINAL REFERENCE NO.:	116:7065a,7068a
TITLE:	Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides
AUTHOR(S):	Davis, Peter D.; Hill, Christopher H.; Lawton, Geoffrey; Nixon, John S.; Wilkinson, Sandra E.; Hurst, Steven A.; Keech, Elizabeth; Turner, Susan E.
CORPORATE SOURCE:	Roche Prod. Ltd., Welwyn Garden City/Herts., AL7 3AY, UK
SOURCE:	Journal of Medicinal Chemistry (1992), 35(1), 177-84 CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 116:41230

GI



I

AB A series of novel inhibitors, i.e., maleimides I (R = H, Me; R1 = (un)substituted indolyl, (un)substituted Ph, naphthyl, benzo[b]thien-3-yl, benzo[b]furan-3-yl, 3-pyrrolyl) of protein kinase C (PKC) is described. These maleimides were derived from the structural lead provided by the indolocarbazoles, staurosporine and K252a. Optimum activity required the imide NH, both carbonyl groups, and the olefinic bond of the maleimide ring. Bisindolylmaleimides were the most active and the potency of these was improved by a chloro substituent at the 5-position of one indole ring (IC50 0.11 μM). In a series of (phenylindolyl)maleimides, nitro derivative I (R = Me, R1 = 2-O2NC6H5) was most active (IC50 0.67 μM). Naphthalene compound I (R = Me, R1 = 1-naphthyl) and benzothiphene compound I (R = Me, R2 = benzo[b]thien-3-yl) showed greater than 100-fold selectivity for inhibition of PKC over the closely related cAMP-dependent protein kinase.

IT 125313-56-6P 125334-43-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and protein kinase C inhibiting activity of)

RN 125313-56-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[1-methyl-2-(methylthio)-1H-indol-3-yl]- (CA INDEX NAME)



RN 125334-43-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[1-methyl-2-(methylsulfinyl)-1H-indol-3-yl]- (CA INDEX NAME)



L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1990:98378 CAPLUS Full-text
DOCUMENT NUMBER: 112:98378
ORIGINAL REFERENCE NO.: 112:16731a,16734a
TITLE: Preparation of 3-(3-indolyl)pyrrole-2,5-diones and analogs as protein kinase inhibitors
INVENTOR(S): Davis, Peter David; Hill, Christopher Huw; Lawton, Geoffrey
PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
SOURCE: Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 328026	A1	19890816	EP 1989-102025	19890206
EP 328026	B1	19930428		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8900865	A	19891025	ZA 1989-865	19890203
CZ 280738	B6	19960417	CZ 1989-752	19890203
SK 278989	B6	19980506	SK 1989-752	19890203
AU 8929658	A	19890810	AU 1989-29658	19890206
AU 623630	B2	19920521		
HU 49348	A2	19890928	HU 1989-554	19890206
HU 201054	B	19900928		
US 5057614	A	19911015	US 1989-307104	19890206
AT 88704	T	19930515	AT 1989-102025	19890206
CA 1320194	C	19930713	CA 1989-590178	19890206
ES 2054890	T3	19940816	ES 1989-102025	19890206
DK 8900558	A	19890811	DK 1989-558	19890207
DK 171891	B1	19970804		
JP 01233281	A	19890919	JP 1989-27741	19890208
JP 07030071	B	19950405		
NO 8900568	A	19890811	NO 1989-568	19890209
NO 172540	B	19930426		
NO 172540	C	19930804		
SU 1799382	A3	19930228	SU 1989-4613492	19890209
FI 8900652	A	19890811	FI 1989-652	19890210
FI 96861	B	19960531		
FI 96861	C	19960910		
US 36736	E	20000613	US 1998-14198	19980127
PRIORITY APPLN. INFO.:			GB 1988-3048 A	19880210
			GB 1988-27565 A	19881125
			EP 1989-102025 A	19890206
			US 1989-307104 A5	19890206

GI



I



II

AB The title compds. (I; R1, R2 = H, alkyl, aryl, etc.; R3 = aryl, heteroaryl; R4-R7 = H, halo, alkyl, alkoxy, etc.; 1 of X, Y = O and the other = O, S, H and OH, H and H) were prepared Thus, 1-(3-bromopropyl)indole (preparation given) was stirred 2 h with (COCl)2 in CH2Cl2 and the product stirred 3 h with 1-methyl-3-indolylacetic acid in CH2Cl2 containing (Me2CH)2NEt to give bis(indolyl)furandione II (R = Br, Z = O) which was converted in 3 steps to II (R = NH2, Z = NH). The latter was stirred 16 h with 1,1'-thiocarbonyldiimidazole in THF to give II (R = NCS, Z = NH) which had IC50 of 0.008 μM for inhibition of protein kinase C in vitro.

IT 125314-93-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of protein kinase inhibitors)

RN 125314-93-4 CAPLUS

CN 2,5-Furandione, 3-(1-methyl-1H-indol-3-yl)-4-[1-methyl-2-(methylthio)-1H-indol-3-yl]- (CA INDEX NAME)



IT 125313-56-6P 125314-43-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as protein kinase inhibitor)

RN 125313-56-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[1-methyl-2-(methylthio)-1H-indol-3-yl]- (CA INDEX NAME)



RN 125334-43-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[1-methyl-2-(methylsulfinyl)-1H-indol-3-yl]- (CA INDEX NAME)



L3 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1989:135048 CAPLUS Full-text
DOCUMENT NUMBER: 110:135048
ORIGINAL REFERENCE NO.: 110:22291a,22294a
TITLE: 3-Pyridiniumindolyl-2-thiolates - new type of functionalized indoles
AUTHOR(S): Gonda, Jozef; Kristian, Pavol
CORPORATE SOURCE: Dep. Org. Chem., P. J. Safarik Univ., Kosice, 041 67, Czech.
SOURCE: Collection of Czechoslovak Chemical Communications (1988), 53(8), 1761-9
CODEN: CCCCAK; ISSN: 0366-547X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:135048
GI



AB 2-Bromomethylphenyl isothiocyanate reacts with pyridines to give 2-isothiocyanatobenzyl-pyridinium bromides I (R = H, 2-, 3-, 4-Me). Deprotonation of these compds. with NaOEt in EtOH or NaH in Me2SO afforded novel type of functionalized indoles, 3-pyridiniumindolyl-2-thiolates II. Reaction of I with KOH or KCN gave products of addition to the NCS group. Structure of I was proven by IR, 1H-, 13C-NMR, and mass spectra and of II (R = H) was confirmed by x-ray diffraction anal.
IT 119476-19-6P 119476-20-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 119476-19-6 CAPLUS

CN Pyridinium, 1-[2-(methylthio)-1H-indol-3-yl]-, iodide (1:1) (CA INDEX NAME)



● I-

RN 119476-20-9 CAPLUS
CN Pyridinium, 2-methyl-1-[2-(methylthio)-1H-indol-3-yl]-, iodide (1:1) (CA INDEX NAME)



● I-

L3 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1971:540653 CAPLUS Full-text
DOCUMENT NUMBER: 75:140653
ORIGINAL REFERENCE NO.: 75:22193a,22196a
TITLE: Tertiary amine oxides. XLIII. Reactions of aromatic N-oxides with alkoxyindoles in the presence of acylating agents
AUTHOR(S): Hamana, Masatomo; Kumadaki, Itsumaro
CORPORATE SOURCE: Fac. Pharm. Sci., Kyushu Univ., Fukuoka, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1971), 19(8), 1669-80
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 1-Methyl-2-ethoxy-(I), 2-ethoxy-(II) and 3-methoxyindoles (III) were treated with N-oxides of pyridines in the presence of an acylating agent. The reaction of I with quinoline 1-oxide (IV) in the presence of tosyl chloride or BzCl progressed in the cold, and 1-methyl-2-ethoxy-3-(2-quinolyl)indole was obtained. The reaction under heating gave V. 2-Chloro- and 4-chloroquinoline 1-oxide as well as pyridine and 4-chloropyridine 1-oxides reacted similarly with I in the presence of tosyl chloride to give the corresponding 3-substituted indoles. Similar reaction of II with IV yielded 2-ethoxy-3-(2-quinolyl)indole(VI). The reaction of III with IV or Et nicotinoate 1-oxide led to the formation of 2-substituted 3-methoxyindoles such as VII; the yield

of VII was poor. The mechanism of the reductive deethoxylation of 2-ethoxy-3-(2-quinolyl or 2-pyridyl)indoles by LiAlH4 was discussed.

IT 33919-94-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 33919-94-7 CAPLUS

CN 1H-Indole, 2-ethoxy-1-methyl-3-(2-pyridinyl)-, compd. with 2,4,6-trinitrophenol (1:1) (CA INDEX NAME)

CM 1

CRN 46960-57-0
CMF C16 H16 N2 O



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1967:516778 CAPLUS Full-text

DOCUMENT NUMBER: 67:116778

ORIGINAL REFERENCE NO.: 67:21995a,21998a

TITLE: Reactions of 3,4-dehydroproline with substituted isatins

AUTHOR(S): Hudson, C. B.; Robertson, Alexander V.

CORPORATE SOURCE: Univ. Sydney, Sydney, Australia

SOURCE: Australian Journal of Chemistry (1967), 20(7), 1521-31
CODEN: AJCHAS; ISSN: 0004-9425

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Substituted isatins having a free NH group react with 3,4-dehydroproline, like isatin itself, to give 3-(1-pyrrolyl)oxindoles. Analysis of the N.M.R. spectra of the 5-nitro and 5,7-dibromo analogs confirms that the isatins condense at their 3- and not their 2-carbonyl groups. N-Alkylisatins form similar products which, depending on the conditions, may react with a further mol. of the isatin to give unstable diadducts whose structures have been determined 20 references.

IT 16176-46-8P 16176-47-9P 16176-48-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 16176-46-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-hydroxy-1-methyl-3-[[1-methyl-3-(1H-pyrrol-1-yl)-1H-indol-2-yl]oxy]- (CA INDEX NAME)



RN 16176-47-9 CAPLUS
CN 2H-Indol-2-one, 3-[[1,5-dimethyl-3-(1H-pyrrol-1-yl)-1H-indol-2-yl]oxy]-1,3-dihydro-3-hydroxy-1,5-dimethyl- (CA INDEX NAME)



RN 16176-48-0 CAPLUS
CN 2H-Indol-2-one, 1-ethyl-3-[[1-ethyl-3-(1H-pyrrol-1-yl)-1H-indol-2-yl]oxy]-1,3-dihydro-3-hydroxy- (CA INDEX NAME)



L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1967:47300 CAPLUS Full-text
DOCUMENT NUMBER: 66:47300
ORIGINAL REFERENCE NO.: 66:8979a,8982a
TITLE: Synthesis of a vat polymer, poly(5,5'-biisatyl[thiophene]indophenine)
AUTHOR(S): Shopov, Ivan
CORPORATE SOURCE: Bulgarian Acad. Sci., Sofia, Bulg.
SOURCE: Journal of Polymer Science, Polymer Letters Edition (1966), 4(12), 1023-8

CODEN: JPYBAN; ISSN: 0360-6384
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The title polymer (I), prepared by polycondensation of thiophene (II) and 5,5'-biisatyl (III), was reduced to its leuco form (IV) to give a polymer vat dye, which oxidized in air to give a polymer with photoelec. and semiconductive properties. Thus, 1.68 g. II in 75 ml. AcOH was added to a cooled solution of 2.92 g. III in 150 ml. H_2SO_4. The solution changed from dark red to dark blue-green with a slight exotherm. After stirring 1 hr., the polymer was precipitated in H_2O, washed with H_2O, extracted with EtOH, and dried to yield 94% I, a dark-blue powder. An aqueous solution of 1.6 g. $Na_2S_2O_6$, 2 g. NaOH, 1 g. I, and 60 ml. H_2O turned darkbrown under N. Filtration under N left IV, which dyed cotton and linen dark-blue. In air, IV oxidized and repptd. I. The oxidation rate was increased by acidifying the solution and using Na_2S as a reducing agent. I had an intensive E.P.R. signal, showed a dark conductivity which decreased with increasing temperature and illumination, and was a p-type semiconductor. I gradually carbonized, but did not burn upon heating.
IT 32198-46-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32198-46-2 CAPLUS
CN Poly[(2,2'-dihydroxy[5,5'-bi-1H-indole]-3,3'-diyl)[2,2'-bithiophene]-5,5'-diyl] (9CI) (CA INDEX NAME)



L3 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1958:25539 CAPLUS Full-text
DOCUMENT NUMBER: 52:25539
ORIGINAL REFERENCE NO.: 52:4639a-i,4640a
TITLE: Structure of isatin blue
AUTHOR(S): Johnson, A. W.; McCaldin, D. J.
CORPORATE SOURCE: Univ. Nottingham, UK
SOURCE: Journal of the Chemical Society (1957) 3470-7
CODEN: JCSOA9; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB New structures were suggested for isatin blue (I) and the related compds. derived by condensation of isatin (II) with either cyclic secondary bases or cyclic α-iminocarboxylic acids. II and piperidine (III) reacted in warm alc. solution (method A) or under anhydrous conditions (method B). II (10 g.) in 250 cc. C_6H_6 refluxed with a Dean and Stark apparatus until all the H_2O was removed, 22 g. dry III added, the heating continued 10 min., a further 0.9 cc.

H_2O collected, and the product isolated gave 9.3 g. 3,3-dipiperidinooxindole (IV). Above 100° IV was converted into I. Method C: Isatin β-p-nitroanil (500 mg.) and 1.5 cc. III shaken 3 hrs. at room temperature in 5 cc. alc. and 45 cc. xylene gave 350 mg. IV. Method C with 1 g. II β-anil (IVa) and 5 g. pyrrolidine (V) in 2 cc. MeOH and 48 cc. xylene gave 985 mg. 3,3-dipyrrolidinooxindole (VI). VI liberated V and became bright blue at 100°. Method C with 0.5 g. IVa and 1.5 cc. morpholine gave 400 mg. 3,3-dimorpholinooxindole (VII). VII was more stable than IV or VI. VII above 120° decomposed with formation of the blue product. 3,3-Di(1,2,3,4-tetrahydro-1-quinolinyl)oxindole was prepared by method A in 44% yield, prisms, m. 296-8° (MeOH). Similarly, 19% 3,3-di(1,2,3,4-tetrahydro-2-isoquinolinyl)oxindole was obtained as prisms, m. 268-70° (decomposition). Solns. in hot MeOH were purple but became colorless on cooling. II (0.5 g.) and 1.1 g. indoline by method A gave 0.2 g. 3,3-diindolinooxindole as prisms, m. 204-6° (MeOH). IV at 60° with Ac_2O gave 500 mg. I as blue prisms, m. 230° (MeOH) (decomposition). L-Pipecolic acid (VIIa) (150 mg.) and 300 mg. II refluxed 0.5 hr. in 15 cc. alc. gave 80 mg. I. Attempted condensation of II and the acid according to the method of Grassmann and Arnim (C.A. 29, 73255) gave N-acetylisatin as the chief product. II (440 mg.) and 100 mg. V warmed 0.5 hr. with 2N AcOH gave 304 mg. compound, $C_{20}H_{15}O_2N_3$ (VIII), crystallized from MeOH. II (650 mg.) and 255 mg. L-proline in 50 cc. phosphate buffer solution refluxed 15 min. gave 181 mg. product which showed an ultraviolet and visible spectrum identical with that of VIII. VII (2.5 g.) in 25 cc. xylene and Ac_2O refluxed 0.5 hr. gave 600 mg. product, $C_{20}H_{15}O_3N_3$, blue prisms. II (0.5 g.) in 10 cc. xylene and 0.5 g. 2-methylpiperidine refluxed 4 hrs. gave 460 mg. blue pigment, $C_{22}H_{19}O_2N_3$. Similarly, 1.8 g. II and 0.6 g. 3-methylpiperidine refluxed 1.5 hrs. in xylene gave 90 mg. blue pigment, $C_{22}H_{19}N_3O_2$.MeOH. Longer heating of the reactants gave a brown tar. II (0.4 g.) and 0.2 g. cis-octahydroindole in xylene refluxed 2 hrs. gave 170 mg. $C_{24}H_{21}O_2N_3$.MeOH. N-Methylisatin (0.5 g.) and 0.5 g. V heated 1 hr. with 25 cc. 2N AcOH gave 465 mg. $C_{22}H_{15}O_2N_3$, infrared spectrum in Nujol showed no medium or strong absorption below 1673 $cm.^{-1}$ Other bands were at 1634, 1599, and 1582 $cm.^{-1}$ II (1 g.) and 0.5 g. isoindoline-HCl heated 10 min. in AcOH gave 130 mg. product which gave a blue solution in concentrated H_2SO_4. Acenaphthenequinone (0.3 g.) and 150 mg. VIIa refluxed 0.5 hr. in 30 cc. alc. gave 179 mg. $C_{29}H_{19}O_2N$. II and III in equimolar amts. gave isatic acid piperidide, prisms, m. 135° (alc.); acetate, needles, m. 135° (50% aqueous MeOH). 5-Bromoisatin (IX) and III gave 5-bromoisatic acid piperidide, yellow prisms, m. 206-8° (alc.), sublimed 140°/0.1 mm.; acetate, m. 138-40°; 2,4-dinitrophenylhydrazone, orange-red needles, m. 371-3° ($PhNO_2$). IX and morpholine gave 5-bromoisatic acid morpholide, needles, m. 208-10° (decomposition); acetate, m. 168° (H_2O). IX (0.5 g.) and 0.4 g. hexamethylenimine in 2 cc. MeOH gave 320 mg. 5-bromo-N,N-hexamethylenisatamide, prisms, m. 165-6° (MeOH). Similarly, 4,5-benzisatin and 600 mg. V gave 300 mg. 3,4-benzisatic acid pyrrolidide, prisms, m. 179-80° (MeOH). I (2 g.) treated with 100 cc. concentrated HNO_3, after the initial reaction warmed for a short period, evaporated to dryness in vacuo, and H_2O added followed by distillation gave 100 mg. steam-volatile material. The product was the same constituent of the residue which was sublimed at 100°/0.1 mm. and gave 700 mg. product, $C_6H_3O_7N_3$, m. 118°, considered to be picric acid. I (2 g.) oxidized in 1% KOH solution at 70° with 2.65 g. $KMnO_4$ gave 650 mg. II and oxalic acid, m. 97-9°. When I was oxidized with excess $KMnO_4$, the products were 300 mg. II and 300 mg. anthranilic acid, m. 142-4°. I (2.2 g.) in 30 cc. AcOH treated 1 hr. at room temperature with 1.7 g. CrO_3 in 57 cc. H_2O gave only 350 mg. II. I (700 mg.) heated 48 hrs. at 185°/0.1 mm. gave 8.5 mg. oxindole, m. 125-7°, together with other compds. not further isolated. This degradation provided further evidence in support of a chromophore containing an N-substituted piperidine in the structure postulated for I. The infrared absorption spectra were given for the I and related compds. both in

N,N-dimethylformamide and in 5N HCl together with spectra for substituted 3,3-diaminooxindoles and substituted isatamides.

IT 112349-77-6, Pyridinium, 2,3,4,5-tetrahydro-1-(2-hydroxyindol-3-yl)-5-(2-oxo-3-indolinylidene)-, hydroxide, inner salt
(as structure of isatin blue)

RN 112349-77-6 CAPLUS

CN Pyridinium, 5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-2,3,4,5-tetrahydro-1-(2-hydroxy-1H-indol-3-yl)-, inner salt (CA INDEX NAME)



L3 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1934:44956 CAPLUS Full-text

DOCUMENT NUMBER: 28:44956

ORIGINAL REFERENCE NO.: 28:5439b-f

TITLE: The existence of favored substitution positions in biphenylene sulfide

AUTHOR(S): Courtot, Charles; Kelner, Izaak

SOURCE: Compt. rend. (1934), 198, 2003-5

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB Biphenylene sulfide sulfone chloride with Zn in boiling H2O gave biphenylene sulfide-monosulfinic acid (I); monohydrate, m. 121°; Na and Ba salts, crystalline, soluble in H2O, acid oxidized in air to the hydrate of the sulfonic acid, m. 172°. I + SOCl2 gave an unstable chloride which reacted with biphenylene sulfide in presence of AlCl3 in CS2 to give (C6H4.S.C6H4]2SO, m. 260°. I + Zn in H2O at 15° gave the disulfide of biphenylene sulfide, m. 175°. Excess of Zn at 90° gave the thiol of biphenylene sulfide (II), m. 81°; Ac derivative, m. 122°; Bz derivative (III), m. 116°; Et ether (by action of EtBr), m. 93°. II was also made from nitrobiphenylene sulfide (C. A. 25, 4872) by reducing, diazotizing, treating with Et xanthate, and hydrolyzing the resulting thioxanthic ester with KOH to the K salt of II. This with BzCl gave III. Therefore the NO2 and SO3H groups enter the biphenylene sulfide mol. in the same position. Nitration of bromobiphenylene sulfide and bromination of nitrobiphenylene sulfide gave identical mononitromonobromobiphenylene sulfides (IV) which were also compared as acetates and benzoates of the corresponding bromoamino compds. Similarly the same nitrobiphenylene sulfide-sulfonic acid (chloride m. 257°) was obtained regardless of the order of substitution. Reduction of IV followed by the Sandmeyer reaction gave dibromobiphenylene sulfide, m. 229°, identical with that obtained by direct bromination. It is concluded that the 2 substituents occupy sym. positions, with respect to the S and biphenylene linkage, in both rings. Cf. C. A. 20, 2155.

IT 97480-91-0P, 3-Isopyrrolinol, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)-
RL: PREP (Preparation)
(preparation of)

RN 876480-91-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[3-hydroxy-5-(2-hydroxy-1H-indol-3-yl)-2H-pyrrol-2-ylidene]- (CA INDEX NAME)



L3 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1934:44955 CAPLUS Full-text
DOCUMENT NUMBER: 28:44955
ORIGINAL REFERENCE NO.: 28:5438f-i,5439a-b
TITLE: Reaction of ninhydrin and isatin with proline and hydroxyproline
AUTHOR(S): Grassmann, W.; v. Arnim, K.
SOURCE: Justus Liebigs Annalen der Chemie (1934), 509, 288-303
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB Triketohydrindene hydrate (I) (2.2 mols.) and 1 mol. proline (II) in H2O at pH 7 at 60° give 83% of the dye III or IV (R = H), m. 176° (decomposition); this results in smaller yields from 2 mols. I and 1 mol. pyrrolidine (V) in boiling AcOH. I (1 mol.) and 1 mol. II in EtOH give 82% of monopyrrolidinylninhydrin, golden yellow, decomposing above 190°; with I at pH 7 68.6% of III results. I and hydroxyproline (VI) in H2O of pH 7 at 40-50° give 76% of a violet dye, III or IV (R = OH), does not m. 275°. I and piperidine (VII) in EtOH give 59% of dipiperidylninhydrin, yellow, m. 131° (decomposition); this is converted by boiling Ac2O to the dye, C23H15O4N, violet with metallic luster; this dye also results from 2 mols. I and 1 mol. VII or 1 mol. piperidine-2-carboxylic acid in AcOH; yields, about 60%. Isatin (2 mols.) and 1 mol. II in AcOH give 75.5% of a dye VIII or IX (R = H), blue needles; in H2O the yield is 46.8%; V gives the same dye; reduction with Zn or TiCl3 gives the leuco compound VI gives 57% of a dye (VIII or IX, R = OH), amorphous. Absorption spectra curves are given for these dyes. The structures of the intermediate compds. are discussed.
IT 857792-04-2P, Isopyrroline, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)- 876480-91-0P, 3-Isopyrrolinol, 5-(2-hydroxy-3-indyl)-2-(2-keto-3(2)-indylidene)-
RL: PREP (Preparation)
(preparation of)
RN 857792-04-2 CAPLUS
CN 2H-Indol-2-one, 3-[3,4-dihydro-5-(2-hydroxy-1H-indol-3-yl)-2H-pyrrol-2-ylidene]-1,3-dihydro- (CA INDEX NAME)



RN 876480-91-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[3-hydroxy-5-(2-hydroxy-1H-indol-3-yl)-2H-pyrrol-2-ylidene]- (CA INDEX NAME)



=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 09:11:27 ON 14 APR 2009